Turning Point Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2013-10-08
- Employees
- 251
- Market Cap
- -
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05828303
- Locations
- 🇺🇸
Local Institution - 2101, Canton, Ohio, United States
🇺🇸Gabrail Cancer Research Center, Canton, Ohio, United States
🇦🇺Local Institution - 2119, Westmead, New South Wales, Australia
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Registration Number
- NCT05828277
- Locations
- 🇪🇸
Local Institution - 4103, Madrid, Spain
🇺🇸Gabrail Cancer Research Center, Canton, Ohio, United States
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
- Conditions
- KRAS Mutation-Related TumorsAdvanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05071183
- Locations
- 🇺🇸
Local Institution - 2107, Houston, Texas, United States
🇺🇸Local Institution - 2102, Virginia Beach, Virginia, United States
🇺🇸Local Institution - 2101, California City, California, United States
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT05001516
- Locations
- 🇺🇸
Local Institution - 0017, Fullerton, California, United States
🇺🇸Local Institution - 0012, Lafayette, Indiana, United States
🇺🇸Local Institution - 0013, Duarte, California, United States
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
- Conditions
- Non Small Cell Lung CancerNon-Small Cell Lung CancerNSCLCAdvanced Solid TumorMetastatic Solid TumorALK Gene Mutation
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04849273
- Locations
- 🇺🇸
Local Institution - 2103, Hackensack, New Jersey, United States
🇺🇸Local Institution - 2102, Fairfax, Virginia, United States
🇰🇷Local Institution - 6304, Seoul, Korea, Republic of
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
- Conditions
- Advanced Solid TumorNon Small Cell Lung CancerMetastatic Solid TumorMedullary Thyroid CancerRET Gene Mutation
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04161391
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Local Institution - 2120, Houston, Texas, United States
🇺🇸Baylor College of Medicine - Baylor Heart Clinic, Houston, Texas, United States
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Conditions
- Metastatic Solid TumorsLymphomaPrimary CNS TumorsLocally Advanced Solid Tumors
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT04094610
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California at Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
- Conditions
- Advanced Solid TumorMET Gene AlterationsMetastatic Solid Tumors
- Interventions
- Drug: elzovantinib (TPX-0022)
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03993873
- Locations
- 🇺🇸
Local Institution - 2102, La Jolla, California, United States
🇺🇸Local Institution - 2108, Orange, California, United States
🇺🇸Local Institution - 2105, Denver, Colorado, United States
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Conditions
- Locally Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT03093116
- Locations
- 🇨🇳
Local Institution - 6504, Shatin, Hong Kong, China
🇺🇸City Of Hope, Duarte, California, United States
🇺🇸Local Institution - 2120, Glendale, California, United States